Claims:

1. A pharmaceutical combined preparation containing a therapeutic protein having SH-groups which are nitrosated and a compound containing thiol groups and having an average molecular weight of at most 10.000.

2. A pharmaceutical combined preparation according to claim 1, characterized in that at least 90% of the present SH-groups are nitrosated.

3. A pharmaceutical combined preparation according to any of claims 1 or 2, characterized in that S-nitroso albumin, S-nitroso orosomucoid, S-nitroso plasminogen activator, S-nitroso fibrinogen, S-nitroso Lys-plasminogen or S-nitroso haemoglobin is contained as the therapeutic protein having nitrosated SH-groups.

4. A pharmaceutical combined preparation according to any of claims 1 or 2, characterized in that reduced glutathione, L-cysteine, N-acetyl cysteine, L-cysteinyl glycine, γ-glutamyl cysteine, penicillamine, penicillamide, N-acetyl penicillamine, N-acetyl penicillamide, homocysteine, captopril, dihydrolipoic acid and/or the oxidized form thereof, which, after administration, is reduced in vivo, is/are contained as the compound containing thiol groups.

5. A pharmaceutical combined preparation according to any of claims 3 or 4, characterized in that S-nitroso albumin is contained as the therapeutic protein having nitrosated SH-groups, and reduced glutathione is contained as the compound containing thiol groups.

6. A pharmaceutical combined preparation according to claim 4, characterized in that a compound occurring in human blood and tissue, in particular reduced glutathione, L-cysteine, L-cysteinyl glycine, γ-glutamyl cysteine or dihydrolipoic acid, is contained as the compound containing thiol groups.

7. A pharmaceutical combined preparation according to any of claims 1 to 6, characterized in that a therapeutic protein obtained by nitrosation is contained in which the degree of nitrosation is made up of S-nitrosation by at least 90% and of N,O,C-nitrosation by at most 10%.